WebMD Health News
Laura J. Martin, MD
May 3, 2011 -- People with atrial fibrillation, a common type of abnormal heart rhythm, are hospitalized twice as often as people without the condition, and costs of treatment are high, a new study suggests.
Not only are people with atrial fibrillation hospitalized more often, they have three times the rate of multiple hospitalizations compared to people without the disorder, and four times as many cardiovascular admissions, according to the study.
Treating people with atrial fibrillation added $26 billion to the nation’s health care bill in just one year, including $6 billion for atrial fibrillation care and $10.1 billion for non-cardiovascular health problems.
“Atrial fibrillation places a huge economic burden on health care payers, patients, and our country,” says Michael H. Kim, MD, of Northwestern University and author of the study. “It is not clear that the country realizes that atrial fibrillation patients are much more likely to have cardiovascular hospitalizations specifically, and more hospitalizations in general.”
Atrial fibrillation is an irregular heart rhythm that occurs when the heart’s upper chambers beat erratically, causing chambers to pump blood inefficiently. It can cause blood to pool and clot in the chambers, increasing the risk of stroke and heart attack.
The condition affects about 3 million American adults, and that number is expected to double over the next 25 years, adding to the cost burden.
Researchers examined data on 89,066 people with atrial fibrillation from two medical records databases that totaled 38 million people. The scientists matched patients with atrial fibrillation with a comparison group without the condition, and followed each pair for 12 months during 2004-2006.
Among key findings:
“We’re not going to impact health care costs or cardiovascular outcomes by just addressing atrial fibrillation itself,” Kim says in a news release. “The large amount of cardiovascular disease among atrial fibrillation patients appears to worsen outcomes and increase costs. This is a sicker population.”
More than 460,000 new cases of atrial fibrillation are diagnosed every year, and it contributes to more than 80,000 deaths annually, according to the study.
“Atrial fibrillation is a significant issue and it is clearly causing primary hospitalizations, but we are likely underestimating its costs,” Kim says.
The study is published in Circulation: Cardiovascular Quality and Outcomes, a journal of the American Heart Association.
It was funded by the pharmaceutical company, Sanofi-Aventis US Inc.
Kim disclosed that he is a research consultant to the drug company and is on its speakers bureau and advisory board. One of the study authors, Mehul R. Dalal, PhD, of Northwestern, is an employee of Sanofi-Aventis. And Stephen Johnston, MA, Bong-Chul Chu, PhD, and Kathy L. Schulman, MA, are employees of Thomson Reuters, which has a research consulting agreement with Sanofi-Aventis.
SOURCES:News release, American Heart Association.Kim, M. Circulation: Cardiovascular Quality and Outcomes, May 3, 2011.
Here are the most recent story comments.View All
© 2014 Ramar Communications |
Site Map |
Privacy Statement |
Copyright & Trademark Notice |
EEO Report |
FCC Public Files |
Closed Captioning |